Track topics on Twitter Track topics that are important to you
Psoriatic arthritis (PsA) is a chronic inflammatory disorder affecting up to 30% of psoriatic patients, worsening patients' quality of life. Secukinumab, a fully humanized monoclonal antibody that selectively inhibits interleukin (IL) 17A, has been recently approved for the treatment of PsA in adults, alone or in association with methotrexate (MTX). In the secukinumab registration studies, the primary endpoint was evaluated at 24 weeks; whether there is an early response in patients with psoriatic arthritis is not well characterized. Furthermore, the registration studies included a hierarchical analysis of end-points that led to a missing evaluation of many secondary endpoints. We report our real life experience with secukinumab in 13 patients with PsA who did not respond to previous therapies. Our patients underwent clinical evaluation for the assessment of PsA severity and inflammation markers at 4 and 16 weeks. Clinical scores and laboratory tests improved at week 4 and 16 with rapid remission of psoriatic lesions and improvements of arthritis. The speed of action of secukinumab and the improvement in the quality of life, underlined by our findings, can be useful in daily clinical practice.
This article was published in the following journal.
Name: The Journal of dermatological treatment
No evidence-based approaches exist to guide the choice of specific biological agent in patients with psoriatic arthritis (PsA). Case reports may provide useful information to help treatment choice in ...
Nail involvement is frequent in patients with psoriasis, especially those with psoriatic arthritis, and can significantly impair quality of life. It is typically difficult to treat compared with skin ...
Patients with psoriasis may be at higher risk of Candida spp. infection. Interleukin (IL)-17 acts in the prevention of those infections; it is also involved in the pathogenesis of psoriasis. Therefore...
A network meta-analysis using randomized controlled trial data compared psoriatic arthritis (PsA) outcomes (American College of Rheumatology [ACR], Psoriasis Area Severity Index [PASI] and Psoriatic A...
Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-...
The investigators propose an open label pragmatic clinical and laboratory study designed to investigate, in detail, the clinical and molecular effects of Interleukin 17 (IL-17) and inhibit...
The purpose of this study is to compare the safety and efficacy of secukinumab monotherapy and adalimumab monotherapy in patients with active psoriatic arthritis who are naïve to biologic...
To demonstrate that the efficacy of secukinumab 300 mg at Week 16 is superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College...
Mild psoriasis not only progresses to moderate-to-severe psoriasis but also precedes systemic inflammation that leads to psoriatic arthritis and cardiovascular comorbidities. By curing mil...
Psoriatic arthritis is related with chronic inflammation and progressive radiographic damages, and it in turn lead to disability and loss in function-ability. Recent advance in treatment p...
A chimeric monoclonal antibody to TNF ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE.
A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.
A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.
A recombinant version of soluble human TNF receptor that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS.
A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
A joint is where two or more bones come together, like the knee, hip, elbow, or shoulder. Joints can be damaged by many types of injuries or diseases, including Arthritis - inflammation of a joint causes pain, stiffness, and swelling with ...
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...